BioSpace News Archive

Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that its fourth quarter and full year 2021 financial results will be released on Thursday, March 3, 2022 before the U.S. financial markets open.

Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, March 3, 2022 to report its fourth quarter and full-year 2021 financial results and discuss recent business highlights.

BioCryst Pharmaceuticals, Inc. announced new long-term efficacy and safety data from the APeX-2 clinical trial evaluating oral, once-daily ORLADEYO® for the prophylactic treatment of hereditary angioedema showing sustained reductions in attack rates and improvement in quality of life among patients living with HAE, regardless of their baseline attack rates and initial responses to ORLADEYO.

Diffusion Pharmaceuticals Inc. announced a significant expansion of its Scientific Advisory Board to include five prominent radiation and medical oncologists to help guide its recently announced clinical program aimed at evaluating the Company’s lead product candidate, trans sodium crocetinate, as an adjunctive treatment for hypoxic solid tumors.

Chimerix announced that preclinical data from the Company’s CMX521 program will be featured in a late-breaking oral presentation session at the International Conference on Antiviral Research on Wednesday, March 23, 2022 from 12:15 – 1:00 pm PT.

BioAdaptives, Inc. (OTCMkts: BDPT) announced today positive results from a study conducted by Stanford Medical School Professor, Lorrin Koran, M.D., regarding the use of Pluripain® to manage the symptoms of Gadolinium Deposition Disease (GDD).

Compugen Ltd., a clinical-stage cancer immunotherapy company and leader in predictive target discovery, reported financial results for the fourth quarter ended December 31, 2021, and full year 2021 and provided an update on recent Company highlights.

Second Genome yesterday hosted a virtual key opinion leader (KOL) event focused on the role of mucosal healing and plasminogen activator inhibitor (PAI)-1/2 in inflammatory bowel disease (IBD), and a briefing on SG-5-00455, the Company’s development candidate for the treatment of IBD.

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its financial results for the fourth quarter of 2021, on Thursday, March 3, 2022, before the U.S. financial markets open.

Ncardia announced today the appointment of Andy Holt as Chief Commercial Officer.